Page 59 - Read Online

Zhang et al. Vessel Plus 2021;5:48 https://dx.doi.org/10.20517/2574-1209.2021.64 Page 13 of 14

and mice. Blood 2019;133:193-204. DOI PubMed PMC
137. Argaw AT, Asp L, Zhang J, et al. Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease. J
Clin Invest 2012;122:2454-68. DOI PubMed PMC
138. Kondziolka D, Lunsford LD, Kestle JR. The natural history of cerebral cavernous malformations. J Neurosurg 1995;83:820-4. DOI
PubMed
139. Maraire JN, Awad IA. Intracranial cavernous malformations: lesion behavior and management strategies. Neurosurgery 1995;37:591-
605. DOI PubMed
140. Moriarity JL, Wetzel M, Clatterbuck RE, et al. The natural history of cavernous malformations: a prospective study of 68 patients.
Neurosurgery 1999;44:1166-71; discussion 1172. PubMed
141. Amoozegar F, Ronksley PE, Sauve R, Menon BK. Hormonal contraceptives and cerebral venous thrombosis risk: a systematic review
and meta-analysis. Front Neurol 2015;6:7. DOI PubMed PMC
142. Flemming KD, Lanzino G. Cerebral cavernous malformation: what a practicing clinician should know. Mayo Clin Proc
2020;95:2005-20. DOI PubMed
143. Chohan MO, Marchiò S, Morrison LA, et al. Emerging pharmacologic targets in cerebral cavernous malformation and potential
strategies to alter the natural history of a difficult disease: a review. JAMA Neurol 2019;76:492-500. DOI PubMed
144. Zabramski JM, Kalani MYS, Filippidis AS, Spetzler RF. Propranolol treatment of cavernous malformations with symptomatic
hemorrhage. World Neurosurg 2016;88:631-9. DOI PubMed
145. Zabramski JM. In reply to the letter to the editor regarding "Propranolol treatment of cavernous malformations with symptomatic
hemorrhage". World Neurosurg 2021;145:513. DOI PubMed
146. You C, Zhao K, Dammann P, et al. EphB4 forward signalling mediates angiogenesis caused by CCM3/PDCD10-ablation. J Cell Mol
Med 2017;21:1848-58. DOI PubMed PMC
147. Wüstehube J, Bartol A, Liebler SS, et al. Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by
activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A 2010;107:12640-5. DOI PubMed PMC
148. Olesen SH, Zhu JY, Martin MP, Schönbrunn E. Discovery of diverse small-molecule inhibitors of mammalian sterile20-like kinase 3
(MST3). ChemMedChem 2016;11:1137-44. DOI PubMed PMC
149. Marchi S, Corricelli M, Trapani E, et al. Defective autophagy is a key feature of cerebral cavernous malformations. EMBO Mol Med
2015;7:1403-17. DOI PubMed PMC
150. Maddaluno L, Rudini N, Cuttano R, et al. EndMT contributes to the onset and progression of cerebral cavernous malformations.
Nature 2013;498:492-6. DOI PubMed
151. Gibson CC, Zhu W, Davis CT, et al. Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation.
Circulation 2015;131:289-99. DOI PubMed PMC
152. Bravi L, Rudini N, Cuttano R, et al. Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice. Proc
Natl Acad Sci U S A 2015;112:8421-6. DOI PubMed PMC
153. Aguilera D, Tomita T, Goldman S, Fangusaro J. Incidental resolution of a radiation-induced cavernous hemangioma of the brain
following the use of bevacizumab in a child with recurrent medulloblastoma. Pediatr Neurosurg 2010;46:303-7. DOI PubMed
154. Weiner GM, Ducruet AF. Fasudil slows development of cavernous malformations. Neurosurgery 2017;80:N25-7. DOI PubMed
155. Shenkar R, Shi C, Austin C, et al. RhoA kinase inhibition with fasudil versus simvastatin in murine models of cerebral cavernous
malformations. Stroke 2017;48:187-94. DOI PubMed PMC
156. McDonald DA, Shi C, Shenkar R, et al. Fasudil decreases lesion burden in a murine model of cerebral cavernous malformation
disease. Stroke 2012;43:571-4. DOI PubMed PMC
157. De Luca E, Pedone D, Moglianetti M, et al. Multifunctional platinum@BSA-Rapamycin nanocarriers for the combinatorial therapy
of cerebral cavernous malformation. ACS Omega 2018;3:15389-98. DOI PubMed PMC
158. Zhao L. New concepts regarding the treatment of cerebral cavernous malformations with symptomatic hemorrhage using propranolol.
World Neurosurgery 2019;124:466. DOI
159. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of
infancy. N Engl J Med 2008;358:2649-51. DOI PubMed
160. Berti I, Marchetti F, Skabar A, Zennaro F, Zanon D, Ventura A. Propranolol for cerebral cavernous angiomatosis: a magic bullet.
Clin Pediatr (Phila) 2014;53:189-90. DOI PubMed
161. Moschovi M, Alexiou GA, Stefanaki K, Tourkantoni N, Prodromou N. Propranolol treatment for a giant infantile brain cavernoma. J
Child Neurol 2010;25:653-5. DOI PubMed
162. Cavalheiro S, Campos HG, Silva da Costa MD. A case of giant fetal intracranial capillary hemangioma cured with propranolol. J
Neurosurg Pediatr 2016;17:711-6. DOI PubMed
163. Reinhard M, Schuchardt F, Meckel S, et al. Propranolol stops progressive multiple cerebral cavernoma in an adult patient. J Neurol
Sci 2016;367:15-7. DOI PubMed
164. Ridker PM, Danielson E, Fonseca FA, et al; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with
elevated C-reactive protein. N Engl J Med 2008;359:2195-207. DOI PubMed
165. Hong KS, Lee JS. Statins in acute ischemic stroke: a systematic review. J Stroke 2015;17:282-301. DOI PubMed PMC
166. Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-
risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22. DOI PubMed
167. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59. DOI PubMed